Tocilizumab for COVID-19: a real 'miracle drug'?

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 32644027)

Published in Infect Dis (Lond) on June 17, 2020

Authors

Sundus Nasim¹, Shariq Haider Hashmi², Dua Azim¹, Sohail Kumar¹, Jasia Nasim¹

Author Affiliations

1: Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
2: NYU Grossman School of Medicine, New York City, NY, USA.

Articles cited by this ↗

Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (Lond) (2020) 5.86